INCY News and Press, Incyte Corporation From 11/04/20

- Numerous abstracts, including 7 oral presentations, highlighting data for ruxolitinib, parsaclisib, tafasitamab and ponatinib to be exhibited Incyte (Nasdaq: INCY) today announced that numerous abstracts highlighting data from its oncology portfolio will be presented at th...

Incyte (NASDAQ:INCY) is scheduled to announce Q3 earnings results on Thursday, November 5th, before market open.The consensus EPS Estimate is $0.76 (-7.3% Y/Y) and the consensus Revenue Estimate is $622.48M (+12.9% Y/Y).Over the last 2 years, INCY has beaten EPS estimates 88% of the time and ...

ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis Latest long-term safety and efficacy data on Olumiant reinforce the medicine's potential to help people living with rheumatoid arthritis (RA) PR Newswire INDIANAPOLIS, Nov. 2, 2...

CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint receptor inhibitor from Sweden's BioInvent in a $95 million deal. Shanghai's Zai Lab...

EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis - Latest baricitinib data highlight long-term efficacy and safety results from BREEZE-AD3 trial - Baricitinib was recently approved by the European Commiss...

- Incyte placed in the top three for third consecutive year Incyte (Nasdaq:INCY) today announced that the company has again been named a top biopharma employer by Science magazine through its Top Employers Survey of the global pharmaceutical and biotech industry. This ye...

Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata - Data support baricitinib's ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA) ...

- Results reinforce that ruxolitinib cream treatment results in a rapid, substantial and sustained reduction in itch - Results also demonstrate improvement in patient-reported perceptions of sleep quality, sleep depth and restoration associated with sleep as measured by the PROM...

The Health Canada accepts for review Incyte's ([[INCY]] +0.2%) marketing application seeking approval of pemigatinib as a treatment of previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with FGFR2 fusion.Pemigatinib is&#x...

Incyte Announces Health Canada Acceptance of the New Drug Submission for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma Canada NewsWire MONTREAL, Oct. 26, 2020 MONTREAL , Oct. 26, 2020 /CNW/ - Incyte (Nasdaq: INCY) today announced that Health...